ProfileGDS5678 / 1440819_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 85% 80% 81% 78% 78% 83% 79% 81% 76% 75% 75% 77% 75% 79% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.3895585
GSM967853U87-EV human glioblastoma xenograft - Control 25.7178380
GSM967854U87-EV human glioblastoma xenograft - Control 35.817681
GSM967855U87-EV human glioblastoma xenograft - Control 45.5472678
GSM967856U87-EV human glioblastoma xenograft - Control 55.3397778
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.871783
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.3461579
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.7888181
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.0637276
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.0454275
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.0032775
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.2961777
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.9982375
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.5513379